Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL-925 for Allergic Conjunctivitis
NCT06293820Phase 2Completed
- Sponsor
- Telios Pharma
- Start
- Apr 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TL-925 in allergic conjunctivitis (AC), sponsored by Telios Pharma. Started Apr 2024; status: completed.
02
Drugs
TL-925
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT06293820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293820.